Trial · NCT03633396
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) | Placebo | -6.0 | Standard Error 1.48 | score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) | Imsidolimab | -6.1 | Standard Error 1.46 | score on a scale | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | Any treatment-emergent adverse event (TEAE) | 20 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | Any treatment-emergent adverse event (TEAE) | 21 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAE related to study drug | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | TEAE related to study drug | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | Severe TEAE | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | Severe TEAE | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | Serious TEAE | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | Serious TEAE | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAE of special interest | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | TEAE of special interest | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAE leading to discontinuation of study treatment | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | TEAE leading to discontinuation of study treatment | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAE leading to study discontinuation | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | TEAE leading to study discontinuation | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAE leading to death | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | TEAE leading to death | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAE related to injection site reaction | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Imsidolimab | TEAE related to injection site reaction | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03633396/results